Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.

Abelin JG, Harjanto D, Malloy M, Suri P, Colson T, Goulding SP, Creech AL, Serrano LR, Nasir G, Nasrullah Y, McGann CD, Velez D, Ting YS, Poran A, Rothenberg DA, Chhangawala S, Rubinsteyn A, Hammerbacher J, Gaynor RB, Fritsch EF, Greshock J, Oslund RC, Barthelme D, Addona TA, Arieta CM, Rooney MS.

Immunity. 2019 Oct 15;51(4):766-779.e17. doi: 10.1016/j.immuni.2019.08.012. Epub 2019 Sep 5.

PMID:
31495665
2.

The Role of Mass Spectrometry and Proteogenomics in the Advancement of HLA Epitope Prediction.

Creech AL, Ting YS, Goulding SP, Sauld JFK, Barthelme D, Rooney MS, Addona TA, Abelin JG.

Proteomics. 2018 Jun;18(12):e1700259. doi: 10.1002/pmic.201700259. Epub 2018 Feb 23. Review.

3.

A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.

Addona TA, Shi X, Keshishian H, Mani DR, Burgess M, Gillette MA, Clauser KR, Shen D, Lewis GD, Farrell LA, Fifer MA, Sabatine MS, Gerszten RE, Carr SA.

Nat Biotechnol. 2011 Jun 19;29(7):635-43. doi: 10.1038/nbt.1899.

4.

Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2.

Boulbes D, Chen CH, Shaikenov T, Agarwal NK, Peterson TR, Addona TA, Keshishian H, Carr SA, Magnuson MA, Sabatini DM, Sarbassov dos D.

Mol Cancer Res. 2010 Jun;8(6):896-906. doi: 10.1158/1541-7786.MCR-09-0409. Epub 2010 May 25.

5.

Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma.

Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, Hall SC, Allen S, Blackman RK, Borchers CH, Buck C, Cardasis HL, Cusack MP, Dodder NG, Gibson BW, Held JM, Hiltke T, Jackson A, Johansen EB, Kinsinger CR, Li J, Mesri M, Neubert TA, Niles RK, Pulsipher TC, Ransohoff D, Rodriguez H, Rudnick PA, Smith D, Tabb DL, Tegeler TJ, Variyath AM, Vega-Montoto LJ, Wahlander A, Waldemarson S, Wang M, Whiteaker JR, Zhao L, Anderson NL, Fisher SJ, Liebler DC, Paulovich AG, Regnier FE, Tempst P, Carr SA.

Nat Biotechnol. 2009 Jul;27(7):633-41. doi: 10.1038/nbt.1546. Epub 2009 Jun 28. Erratum in: Nat Biotechnol. 2009 Sep;27(9):864.

6.

Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification.

Jaffe JD, Keshishian H, Chang B, Addona TA, Gillette MA, Carr SA.

Mol Cell Proteomics. 2008 Oct;7(10):1952-62. doi: 10.1074/mcp.M800218-MCP200. Epub 2008 Jun 4.

7.

Selective detection of glycopeptides on ion trap mass spectrometers.

Sullivan B, Addona TA, Carr SA.

Anal Chem. 2004 Jun 1;76(11):3112-8.

PMID:
15167790
8.

A novel 110 kDa form of myosin XVIIIA (MysPDZ) is tyrosine-phosphorylated after colony-stimulating factor-1 receptor signalling.

Cross M, Csar XF, Wilson NJ, Manes G, Addona TA, Marks DC, Whitty GA, Ashman K, Hamilton JA.

Biochem J. 2004 May 15;380(Pt 1):243-53.

9.
10.

Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin.

Topham PS, Kawachi H, Haydar SA, Chugh S, Addona TA, Charron KB, Holzman LB, Shia M, Shimizu F, Salant DJ.

J Clin Invest. 1999 Dec;104(11):1559-66. Erratum in: J Clin Invest 2000 Jan;105(1):125.

11.

De novo peptide sequencing via tandem mass spectrometry.

Dancík V, Addona TA, Clauser KR, Vath JE, Pevzner PA.

J Comput Biol. 1999 Fall-Winter;6(3-4):327-42.

PMID:
10582570
12.

Cloning of a yeast 8-oxoguanine DNA glycosylase reveals the existence of a base-excision DNA-repair protein superfamily.

Nash HM, Bruner SD, Schärer OD, Kawate T, Addona TA, Spooner E, Lane WS, Verdine GL.

Curr Biol. 1996 Aug 1;6(8):968-80.

Supplemental Content

Loading ...
Support Center